Last viewed:
INCY
Prices are updated after-hours
INCY
|
$52.3
-0.98%
-0.99%
2.2M
|
Health Technology
(0.0% 1d)
(-9.3% 1m)
(-29.8% 1y)
(-0.9% 2d)
(-0.7% 3d)
(-2.0% 7d)
(19.17%
volume)
Earnings Calendar: 2024-02-13
Market Cap: $ 11,742,716,494
http://www.incyte.com
Sec
Filling
|
Patents
| 1456 employees
(US) Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
Drugs
JAKAFI
(ruxolitinib )
PEMAZYRE
(pemigatinib )
add to watch list
Paper trade
email alert is off
Press-releases
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsight
Published: 2024-04-15
(Crawled : 22:00)
- prnewswire.com
INCY
|
$52.3
-0.98%
-0.99%
2.2M
|
Health Technology
| -2.02%
| O: -0.17%
H: 1.41%
C: -0.22%
t-cell
for
therapy
growth
market
Incyte to Report First Quarter Financial Results - April 11, 2024
Published: 2024-04-11
(Crawled : 21:00)
- biospace.com/
INCY
|
$52.3
-0.98%
-0.99%
2.2M
|
Health Technology
| -4.82%
| O: 0.62%
H: 1.17%
C: -0.76%
first
report
financial
results
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
Published: 2024-04-01
(Crawled : 12:30)
- globenewswire.com
INCY
|
$52.3
-0.98%
-0.99%
2.2M
|
Health Technology
| -8.66%
| O: -0.6%
H: 0.0%
C: -0.58%
license
collaboration
asia
agreement
china
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
Published: 2024-04-01
(Crawled : 17:00)
- biospace.com/
INCY
|
$52.3
-0.98%
-0.99%
2.2M
|
Health Technology
| -8.66%
| O: -0.6%
H: 0.0%
C: -0.58%
license
collaboration
asia
agreement
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Published: 2024-03-27
(Crawled : 00:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
| -7.26%
| O: -0.26%
H: 0.0%
C: 0.0%
LLY
|
News
|
$726.31
-2.63%
-0.04%
3.5M
|
Health Technology
| -6.27%
| O: 0.49%
H: 0.84%
C: -0.07%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
| -5.89%
| O: 1.06%
H: 0.0%
C: 0.0%
INCY
|
$52.3
-0.98%
-0.99%
2.2M
|
Health Technology
| -7.43%
| O: -0.09%
H: 1.42%
C: 1.1%
ibi310
first
cancer
colon
therapy
study
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-03-13
(Crawled : 23:00)
- biospace.com/
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
| -4.76%
| O: -0.23%
H: 0.0%
C: 0.0%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
| -5.42%
| O: -0.07%
H: 0.09%
C: -0.7%
XNCR
|
$18.385
-2.98%
-3.07%
830K
|
Health Technology
| -19.39%
| O: -0.66%
H: 4.19%
C: 3.13%
MOR
|
News
|
$17.96
-0.5%
-0.5%
180K
|
Health Technology
| -1.05%
| O: 0.22%
H: 0.22%
C: -0.93%
INCY
|
$52.3
-0.98%
-0.99%
2.2M
|
Health Technology
| -11.76%
| O: 0.03%
H: 1.47%
C: -0.72%
year
update
financial
results
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
Published: 2024-03-12
(Crawled : 00:00)
- prnewswire.com
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
| -4.21%
| O: 0.01%
H: 0.0%
C: 0.0%
INCY
|
$52.3
-0.98%
-0.99%
2.2M
|
Health Technology
| -13.88%
| O: -0.12%
H: 0.3%
C: -2.29%
preclinical
meeting
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
Published: 2024-03-05
(Crawled : 06:00)
- prnewswire.com
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
| -1.49%
| O: 1.17%
H: 0.0%
C: 0.0%
INCY
|
$52.3
-0.98%
-0.99%
2.2M
|
Health Technology
| -12.34%
| O: 0.4%
H: 0.38%
C: -1.77%
lung
cancer
treatment
therapeutics
china
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
Published: 2024-03-04
(Crawled : 14:30)
- biospace.com/
INCY
|
$52.3
-0.98%
-0.99%
2.2M
|
Health Technology
| -11.35%
| O: 0.34%
H: 0.89%
C: 0.79%
meeting
growing
Knight Therapeutics Announces Launch of Minjuvi® in Brazil
Published: 2024-02-29
(Crawled : 12:30)
- globenewswire.com
XNCR
|
$18.385
-2.98%
-3.07%
830K
|
Health Technology
| -19.35%
| O: 2.68%
H: 2.22%
C: -1.92%
INCY
|
$52.3
-0.98%
-0.99%
2.2M
|
Health Technology
| -12.72%
| O: 0.38%
H: 0.0%
C: -3.07%
minjuvi
brazil
therapeutics
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount
0000879169-24-000070
4
2024-04-02
2024-03-28
Buy
A
403
15785
0000879169-24-000069
4
2024-04-02
2024-03-28
Buy
A
413
13115
0000950170-24-039366
4
2024-04-01
2024-03-28
Buy
A
543
33447981
0000950170-24-039366
4
2024-04-01
2024-03-28
Buy
A
543
2970073
0000879169-24-000060
4
2024-02-16
2024-02-14
Buy
A
41577
502333